Breast cancer; Genetic; Polygenic risk scores; PRS; Risk; Screening; Breast Neoplasms; Early Detection of Cancer; Female; Genetic Predisposition to Disease; Genetic Risk Score; Humans; Multifactorial Inheritance; Preventive Medicine; Risk Assessment; Medicine (all)
Abstract :
[en] Despite screening programmes, numerous clinical studies and new breast imaging techniques, breast cancer incidence for women continues to rise. The arrival of predictive and personalized medicine could clearly redefine our screening recommendations. One promising approach to improving screening would be to use tools to predict the risk of developing breast cancer, including polygenic risk scores (PRS). This approach will enable us to offer women risk-based screening by adapting the frequency, type and age of screening. This article reviews some definitions of the PRS and breast cancer screening. We also explain the risk assessment models that have been developed and the various studies underway on personalized screening.
Disciplines :
Genetics & genetic processes
Author, co-author :
CREVECOEUR, Julie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique
Docampo, E.; CHU Liège, Belgium
Martin, Marie ; Université de Liège - ULiège > Département des sciences cliniques
Bours, Vincent ; Université de Liège - ULiège > GIGA > GIGA Cancer - Human Genetics
Language :
French
Title :
INTÉRÊT DE L’UTILISATION DES SCORES DE RISQUES POLYGÉNIQUES DANS LE DÉPISTAGE DU CANCER DU SEIN ET LA MÉDECINE DE PRÉVENTION
Kim G, Bahl M. Assesing risk of breast cancer: a review of risk prediction models. J Breast Imaging 2021;3:144-55.
Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108:2205-40.
Carver T, Hartley S, Lee A, et al. CanRisk Tool - A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomarkers Prev 2021;30:469-73.
French DP, Astley S, Brentnall AR, et al. What are the benefits and harms of risk stratifed screening as part of the NHS breast screening programme? Study protocol for a multi-site nonrandomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer 2020;20:570.
Brooks JD, Nabi HH, Andrulis IL, et al. Personalized risk assessment for prevention and early detection of breast cancer: integration and implementation (PERSPECTIVE I&I). J Pers Med 2021;11:511.
Esserman L, Eklund M, van’t Veer L, et al. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res Treat 2021;189:593-8.
Rouge-Bugat ME, Balleyguier C, Laurent N, et al. MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40-70: Focus on recruitment strategy in France. La Presse Medicale Open 3 2022;100022:1-4.
Yang X, Kar S, Antoniou A, Pharoah P. Polygenic scores in cancer. Nat Rev Cancer 2023;23:619-30.
Choi SW, Mak TS, O’Reilly PF. A guide to performing polygenic risk score analyses. Nat Protoc 2020;15:2759-72.
Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet 2019;104:21-34.
Dépistage organisé du cancer du sein en Région wallonne - Rapport d’activités 2007-2017. CCR (Centre Communautaire de Référence pour le dépistage des cancers). Disponible sur: https://www.ccref.org/pro/pdf/publications/CCR_depistage_cancer_sein_rapport_2007-2017_impression.pdf
Institut National du Cancer (INCA). Cancer du sein, quelles modalités de dépistage pour quelles femmes. INCA, 2018.
Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
Tyrer J, Dufy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 2019;21:1708-18.
Cintolo-Gonzalez JA, Braun D, Blackford AL, et al. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat 2017;164:263-84.
Yang X, Eriksson M, Czene K, et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J Med Genetics 2022;59:1196-205.
Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic version 1.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:77-102.
Saghatchian M, Abehsera M, Yamgnane A, et al. Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. Breast Cancer Res Treat 2022;192:375-83.
Barnes DR., Rookus MA, McGuffog L, et al. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med 2020;22:1653-66.
Berga-Švitina E, Maksimenko J, Miklasevics E, et al. Polygenic risk score predicts modified risk in BRCA1 pathogenic variant c.4035del and c.5266dup Carriers in Breast Cancer Patients. Cancers (Basel) 2023;15:2957.
Kuchenbaecker KB, McGuffog, L, Barrowdale D, et al. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2017;109:djw302.
Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34.
Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cander 2020;20:417-36.
Kaleconski J, Régnier-Denois V, Ouédraogo S, et al. Dépistage organisé ou individuel du cancer du sein? Attitudes et représentations des femmes. Santé Publique 2015;27:213-20.
